RALTITREXED
Raltitrexed
CAS: 112887-68-0
Molecular Formula: C21H22N4O6S
RALTITREXED - Names and Identifiers
RALTITREXED - Physico-chemical Properties
| Molecular Formula | C21H22N4O6S |
| Molar Mass | 458.49 |
| Density | 1.49±0.1 g/cm3(Predicted) |
| Melting Point | 176-1800C |
| Solubility | DMSO : ≥ 20 mg/mL mother liquor preservation: sub-package and freeze storage to avoid repeated freezing and thawing;-20 ℃,1 month;-80 ℃,6 months (after dilution, the solution temperature is low and storage may precipitate, as far as possible to use the current preparation) Cell experiment: dissolve with DMSO first: dilute with culture medium then, and the dilution process is recommended to be carried out in stages to avoid too fast concentration change leading to compound precipitation. If the compound is precipitated during the dilution process, it can be redissolved by ultrasound. During dilution, ensure that the final concentration of DMSO in the working fluid should be below 0.1% as far as possible, and the maximum should not exceed 0.5%, and set up a DMSO control group with corresponding concentration. Animal experiment: Dissolve with DMSO first: dilute with water or normal saline, etc. The dilution process is recommended to be carried out in sections to avoid excessive concentra |
| Appearance | solid |
| Color | off-white to light yellow |
| pKa | 3.50±0.10(Predicted) |
| Storage Condition | 2-8°C |
| Refractive Index | 1.638 |
| MDL | MFCD12828867 |
| Physical and Chemical Properties | Light yellow powder. Soluble in water. Monohydrate: C2lH22N4O6S? H2O. Melting point 180-184 °c. |
| Use | Strong inhibitory effect on colon cancer cell lines |
| Target | Thymidylate synthase |
RALTITREXED - Risk and Safety
| Risk Codes | R36/38 - Irritating to eyes and skin. R25 - Toxic if swallowed R61 - May cause harm to the unborn child |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S37/39 - Wear suitable gloves and eye/face protection S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S53 - Avoid exposure - obtain special instructions before use. |
| UN IDs | UN 2811 6.1 / PGIII |
| WGK Germany | 2 |
RALTITREXED - Reference
| Reference Show more | 1: Surmont VF, van Meerbeeck JP. Raltitrexed in mesothelioma. Expert Rev Anticancer Ther. 2011 Oct;11(10):1481-90. Review. PubMed PMID: 21999120. 2: Wilson KS, Malfair Taylor SC. Raltitrexed: optimism and reality. Expert Opin Drug Metab Toxicol. 2009 Nov;5(11):1447-54. Review. PubMed PMID: 19863453. 3: Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review. PubMed PMID: 18462574. 4: Cao S, Bhattacharya A, Durrani FA, Fakih M. Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Expert Opin Pharmacother. 2006 Apr;7(6):687-703. Review. PubMed PMID: 16556086. 5: Van Cutsem E, Cunningham D, Maroun J, Cervantes A, Glimelius B. Raltitrexed: current clinical status and future directions. Ann Oncol. 2002 Apr;13(4):513-22. Review. PubMed PMID: 12056700. |
RALTITREXED - Nature
Open Data Verified Data
light yellow powder. Soluble in water. Raltitrexed Monohydrate: C21H22 N406 S.H2 0. Light grass green powder. Melting Point 18 0~184 deg C.
Last Update：2024-01-02 23:10:35
RALTITREXED - Preparation Method
Open Data Verified Data
2,6-= methyl -4(3H)-quinazolinone was alkylated with tert-pentalyloxymethyl chloride and then bromonated with N-bromosuccinimide, 6-(bromomethyl) -2-methyl -3-[(tert-valeryloxy) methyl]-4(3H)-quinazolinone is obtained. The material and N-[5-methylaminothiophene-2-carbonyl]-L-glutamic acid Diethyl ester condensation, product and sodium hydroxide in ethanol solution at room temperature stirring hydrolysis, and simultaneous deprotection, then acidification results in raltitrexed.
Last Update：2022-01-01 09:09:08
RALTITREXED - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.181 ml | 10.905 ml | 21.811 ml |
| 5 mM | 0.436 ml | 2.181 ml | 4.362 ml |
| 10 mM | 0.218 ml | 1.091 ml | 2.181 ml |
| 5 mM | 0.044 ml | 0.218 ml | 0.436 ml |
Last Update：2024-01-02 23:10:35
RALTITREXED - Use
Open Data Verified Data
developed by Zeneca, UK, marketed under the trade name Tomudex in AstraZenca, UK, 1996. Thymidylate synthase inhibitor. For the treatment of colon cancer, rectal cancer. It is a new type of anticancer drug, which is mainly used in the first-line treatment of advanced colorectal cancer that is intolerant or not suitable for 5-Fu treatment.
Last Update：2022-01-01 09:09:08
Supplier List
Spot supply
Product Name: (S)-2-(5-(methyl((2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl)amino)thiophene-2-carboxamido)pentanedioic acid Visit Supplier Webpage Request for quotationCAS: 112887-68-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: (S)-2-(5-(methyl((2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl)amino)thiophene-2-carboxamido)pentanedioic acid Visit Supplier Webpage Request for quotationCAS: 112887-68-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History